204 related articles for article (PubMed ID: 26586936)
21. Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53.
Ding W; Tong Y; Zhang X; Pan M; Chen S
Sci Rep; 2016 Jan; 6():19793. PubMed ID: 26795951
[TBL] [Abstract][Full Text] [Related]
22. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
23. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
24. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
25. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells.
Kapp N; Stander XX; Stander BA
Anticancer Drugs; 2018 Jun; 29(5):429-439. PubMed ID: 29561307
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
27. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
[TBL] [Abstract][Full Text] [Related]
28. Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer.
Meng C; Lu Z; Fang M; Zhou X; Dai K; Zhang S; Luo J; Luo Z
Int J Clin Exp Pathol; 2014; 7(11):7622-32. PubMed ID: 25550798
[TBL] [Abstract][Full Text] [Related]
29. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.
Matsui Y; Watanabe J; Ding S; Nishizawa K; Kajita Y; Ichioka K; Saito R; Kobayashi T; Ogawa O; Nishiyama H
BJU Int; 2010 Feb; 105(4):558-64. PubMed ID: 19583730
[TBL] [Abstract][Full Text] [Related]
30. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Temmink OH; Hoebe EK; Fukushima M; Peters GJ
Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
[TBL] [Abstract][Full Text] [Related]
32. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
34. ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo.
Sun XP; Zhang X; He C; Qiao H; Jiang X; Jiang H; Sun X
J Int Med Res; 2012; 40(4):1251-64. PubMed ID: 22971477
[TBL] [Abstract][Full Text] [Related]
35. Sageone, a diterpene from Rosmarinus officinalis, synergizes with cisplatin cytotoxicity in SNU-1 human gastric cancer cells.
Shrestha S; Song YW; Kim H; Lee DS; Cho SK
Phytomedicine; 2016 Dec; 23(13):1671-1679. PubMed ID: 27823632
[TBL] [Abstract][Full Text] [Related]
36. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Lei L; Xie X; He L; Chen K; Lv Z; Zhou B; Li Y; Hu W; Zhou Z
Invest New Drugs; 2021 Apr; 39(2):362-376. PubMed ID: 32981006
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.
Guruswamy S; Rao CV
Int J Oncol; 2009 Nov; 35(5):1037-43. PubMed ID: 19787257
[TBL] [Abstract][Full Text] [Related]
38. Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
Pham MH; Delestre L; Dewitte A; Wattez N; Lepretre F; Lansiaux A
Anticancer Res; 2015 Nov; 35(11):5983-91. PubMed ID: 26504021
[TBL] [Abstract][Full Text] [Related]
39. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Nagashima F; Boku N; Ohtsu A; Yoshida S; Hasebe T; Ochiai A; Sakata Y; Saito H; Miyata Y; Hyodo I; Ando M
Jpn J Clin Oncol; 2005 Dec; 35(12):714-9. PubMed ID: 16303791
[TBL] [Abstract][Full Text] [Related]
40. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
